Stay updated on Cabozantinib for Young Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib for Young Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib for Young Solid Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or revision in the context of a phase I trial studying the side effects and optimal dosage of cabozantinib S-malate in treating younger patients with recurrent or refractory solid tumors.
    Difference
    0.1%
    Check dated 2024-06-06T14:30:34.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for study participants, including specific health conditions and prior treatments required. The new criteria specify body surface area requirements and other health-related conditions for inclusion in the study.
    Difference
    52%
    Check dated 2024-05-22T20:57:38.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:46:54.000Z thumbnail image

Stay in the know with updates to Cabozantinib for Young Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Young Solid Tumors Clinical Trial page.